Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes

In this fifth installment, Ms Carroll discusses strategies for managing adverse events associated with abemaciclib, emphasizing the importance of patient involvement and personalized care. She underscores the value of maintaining open communication and regular touchpoints with patients to address concerns, build trust, and ensure adherence to therapy. These strategies aim to improve the quality of life for patients on abemaciclib.

In this third installment, Dr Moore shares insights from the TRADE study, which evaluated a dose-escalation strategy for abemaciclib in patients with HR-positive, HER2-negative, high-risk breast cancer. Dr Moore emphasizes the importance of combining TRADE study findings with real-world evidence to refine dose-escalation strategies and improve patient outcomes.